Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group said its independently developed drug SYS6010, a humanised EGFR-targeting antibody-drug conjugate, has received another Breakthrough Therapy Designation in China for use as a monotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma who have failed platinum-based chemotherapy and immunotherapy. The company highlighted the heavy disease burden of esophageal squamous cell carcinoma in China, where cases and deaths account for about half of the global total, underscoring a significant unmet medical need.
Clinical studies of SYS6010 for this indication have shown what CSPC describes as breakthrough efficacy versus existing therapies, with meaningful clinical benefits and a favourable safety profile for relapsed patients. The group has launched and is accelerating a Phase III confirmatory trial in esophageal squamous cell carcinoma alongside multiple Phase III studies in other solid tumours, and expects the new designation to speed development, regulatory review, and market launch while reinforcing its oncology pipeline and competitive edge in antibody-drug conjugates.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated drug maker focused on innovative therapies, including antibody-drug conjugates targeting major oncology indications. The group develops and commercializes treatments for high-burden diseases in China and globally, aiming to strengthen its presence in the competitive cancer therapeutics market.
YTD Price Performance: -2.73%
Average Trading Volume: 84,573,293
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.33B
See more data about 1093 stock on TipRanks’ Stock Analysis page.